Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant. It is used for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Drug product containing Sterling’s Deflazacort is commercialized in Europe and USA.
US DMF was submitted to FDA on 03/02/2016 and the following number was assigned n. 30313.
Warning: Invalid argument supplied for foreach() in /srv/users/serverpilot/apps/sterling2019/public/wp-content/themes/sterling/single.php on line 64